Stergiou said the delayed timeline for reaching the final event trigger has increased optimism for the Regal trial. ・The CEO also disclosed that some Regal patients remain on treatment more than three ...

Other institutions, including Mariner and Ameritas Investment Partners, also increased exposure to the stock. ・Sellas said on Tuesday that its Phase 3 Regal AML study had reached 78 events as of May ...

The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...

AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...